#amiodarone #thyroid-dysfunction #thyrotoxicosis #drug-toxicity #antiarrhythmic-drugs

Evaluation and Treatment of Amiodarone-Induced Thyroid Disorders

Authors, Journal, Affiliations, Type, DOI

Authors: Dorina Ylli, Leonard Wartofsky, Kenneth D. Burman
Journal: The Journal of Clinical Endocrinology & Metabolism
Year / Volume: 2021, Vol. 106, No. 1, pp. 226–236
Affiliations: Endocrine Section, MedStar Washington Hospital Center, Washington DC; Faculty of Medicine, University of Medicine, Tirana, Albania
Type: "Approach to the Patient" — case-based clinical review
DOI: 10.1210/clinem/dgaa686

Overview

Amiodarone is a class III antiarrhythmic containing 37% iodine by weight. Deiodination releases large amounts of iodine that can impair thyroid function — causing hypothyroidism or thyrotoxicosis in approximately 20% of treated patients. Both iodine-related and direct cytotoxic mechanisms contribute, independently of dose. This review covers epidemiology, pathophysiology, and a personalised management algorithm for each form of amiodarone-induced thyroid disorder, anchored by a case of Type 2 AIT presenting as ventricular tachycardia storm requiring ECMO.

Keywords

Thyroid, thyrotoxicosis, hypothyroidism, amiodarone, thyroiditis, management

Key Takeaways

Case Presentation

54-year-old man with CAD/prior MI; presented with sustained VT → frequent ICD shocks → ICU intubation → ECMO
Amiodarone at 200 mg/day for 2 years, recently increased to 150 mg twice daily
Thyroid function: elevated FT4 2.42 ng/dL (normal 0.76–1.46), normal T3 90 ng/dL, suppressed TSH 0.026 uIU/mL — no prior thyroid history

Epidemiology of Thyroid Dysfunction in Amiodarone-Treated Patients

Overall incidence of amiodarone-induced thyroid disorders: 2–24%
AIH (hypothyroidism): More common; onset <3 months in 10–20% of cases; onset >1 year in 5–10%; median 183 days to onset
- Higher incidence in: women (F:M ratio 1.5:1; AIH 19.2% women vs 13.3% men in n=1972 meta-analysis), iodine-replete areas (22%), patients with underlying Hashimoto thyroiditis (most common risk factor)
AIT (thyrotoxicosis): Less common; incidence 5–10%; median 720 days to onset
- Higher incidence in: men (3.9–8.5% vs 0.4% women), iodine-deficient areas (10%)
- AIT type 2 more prevalent in iodine-sufficient areas
26% subclinical hypothyroidism in a cohort of 267 amiodarone-treated patients; 5% thyrotoxicosis (mostly subclinical)
Thyroid toxicity is NOT dose-dependent — similar risk on low and high doses
AIT carries significant morbidity/mortality: 23% ICU mortality when thyroid storm complicates AIT

Mechanisms of Amiodarone-Induced Thyroid Disorder

Each 200 mg amiodarone tablet contains 75 mg iodine; ~7 mg free iodine released per tablet — far exceeding normal daily iodine requirement (0.15–0.30 mg)
Wolff-Chaikoff effect: Iodine overload inhibits thyroid hormone organification → ↓ T3/T4 → ↑ TSH. "Escape" restores normal function; failure to escape → persistent AIH
Jod-Basedow phenomenon: In glands with autonomous function (multinodular goiter, Graves'), surfeit iodine → uncontrolled hormone overproduction → Type 1 AIT; more common in iodine-deficient areas
Iodine overload may also inhibit pituitary type 2 deiodinase (D2) → ↓ negative feedback → ↑ TSH (mechanism not fully elucidated)

Amiodarone inhibits peripheral deiodinases → ↓ T4-to-T3 conversion → ↓ serum T3, ↑ rT3 (reverse T3)
Amiodarone or desethylamiodarone (active metabolite) inhibits T3 nuclear receptor binding → ↓ thyroid hormone gene expression
Direct cytotoxic/apoptotic effect on thyroid follicular cells → destructive thyroiditis (basis of Type 2 AIT)
Result in euthyroid patients on amiodarone: transient ↑ TSH, FT4, rT3 in first month → normalises over 3–6 months; T3 remains persistently low (deiodinase inhibition)

Clinical Manifestations and Diagnosis

Amiodarone-Induced Hypothyroidism (AIH)

Due to Wolff-Chaikoff effect failure + underlying autoimmune thyroiditis (positive TPO or thyroglobulin antibodies)
Degree: subclinical or overt
60% of AIH is transient — resolves 2–4 months after amiodarone cessation (more common if no pre-existing thyroid abnormality)

Amiodarone-Induced Thyrotoxicosis (AIT) — Type 1

Predisposed: autonomous thyroid tissue (multinodular goiter, Graves'), iodine-deficient areas
Onset: typically within 2–6 months of initiation
Biochemistry: low TSH, high FT4, normal/high FT3/T3, elevated TSH receptor antibodies in Graves'

AIT — Type 2

Mechanism: direct cytotoxicity → destructive thyroiditis → hormone release
Onset: later (27–32 months); can also occur years after or even after discontinuation (7–16 months post-cessation in 7% of cases)
23% develop AIT after amiodarone withdrawal
Resembles subacute thyroiditis: thyrotoxicosis → euthyroidism → hypothyroidism (17% become permanently hypothyroid vs 5% in non-amiodarone subacute thyroiditis)
More frequent than Type 1 overall

Mixed Type 1/Type 2

Features of both types present simultaneously; diagnosis often made after failure of monotherapy

Diagnostic Tools

Biochemical Laboratory Studies

AIH: elevated TSH, low/normal FT4; may have positive TPO/TG antibodies
AIT Type 1 vs Type 2: both show low TSH + high FT4; Type 1 may have elevated TSH receptor antibodies (Graves'), underlying goiter
Presence of positive anti-TG or anti-TPO antibodies does NOT exclude Type 2 AIT
Beta-glucuronidase (lysosomal enzyme released during inflammation): higher in Type 2 vs Type 1 AIT; similar to subacute thyroiditis — promising but not widely adopted
IL-6 and CRP: conflicting evidence, limited clinical discriminatory value

Thyroid Ultrasound and Color Flow Doppler Sonography

Type 1 AIT: goiter or structural abnormality; normal or increased vascularity on colour Doppler
Type 2 AIT: normal/small gland pre-amiodarone; distorted architecture (thyroiditis); reduced/normal vascularity — key discriminating finding
In iodine-deficient areas small/nodular goiter may occur in Type 2; the diagnostic clue remains reduced vascularity
Experienced sonographer is essential

Nuclear Imaging

RAI uptake: low in both Type 1 and Type 2 (iodine load from amiodarone saturates uptake) → cannot distinguish types; also not useful for treatment
99mTcO4⁻: mostly very low/absent in both types — not discriminatory
MIBI (99mTc-sestamibi): Reduced/absent uptake in apoptotic tissue → increased in Type 1, reduced in Type 2, intermediate in mixed. Promising (Piga n=20) but limited data; widely available in nuclear medicine

Management of Amiodarone-Induced Thyroid Disorders

Management of AIH

Treat with levothyroxine at appropriate starting dose; adjust gradually based on FT4/FT3/TSH and cardiac status
Too-rapid dose escalation → risk of precipitating arrhythmias
Amiodarone can be continued if necessary for cardiac arrhythmia
If amiodarone discontinued → hypothyroidism may resolve (especially if no pre-existing thyroid disease)

Management of Type 1 AIT

Methimazole (preferred): 40–60 mg/day; aggressive dosing up to 120 mg/day (30 mg q6h) in severe cases
Methimazole preferred over PTU (lower hepatotoxicity)
Potassium perchlorate add-on for methimazole failure (not available in USA; sodium perchlorate as alternative)
Lithium adjunct to antithyroid drugs — speeds recovery (limited by side effects)
If methimazole fails at 3–4 weeks → suspect mixed type 1/2
ETA guidelines: continue amiodarone for life-threatening arrhythmias with poor prognosis
If amiodarone withdrawn: continue methimazole until urinary iodine normalises (6–18 months)
75% of patients restarting amiodarone risk another AIT episode

Management of Type 2 AIT

Prednisone cornerstone: 30–40 mg/day for 2–4 weeks, then taper over 2–3 months
Self-limited in many cases; mild/stable thyrotoxicosis may be watched without pharmacologic therapy
Failed prednisone → combined IV methylprednisolone + oral prednisone (Campi protocol, n=4; limited evidence)
IV glucocorticoids not clearly superior to oral in Type 2 AIT (n=3 study)
Prednisone response: FT3/TT3 normalisation expected within average 8 days
Amiodarone continuation feasible in Type 2 (self-limited process); recurrence rate 6–75% if continued
After glucocorticoid discontinuation: 16% will be permanently hypothyroid

Management of Mixed Type 1/2 AIT

Suspected after monotherapy failure
Treat with both methimazole (40 mg/day) + prednisone (40 mg/day) simultaneously
If FT3/TT3 declines >50% → Type 2 more likely → taper thionamide
Once response seen → taper one drug; no improvement → thyroidectomy

Thyroidectomy in AIT

ETA indications:
1. Progressive cardiac deterioration or reduced LVEF with increased mortality risk
2. Severe underlying cardiac disease (e.g., ARVD) or malignant arrhythmias
3. Unresponsive to aggressive methimazole + corticosteroids
Capellani et al. (n=207): lower 5- and 10-year overall and cardiac-specific mortality in surgery vs medical therapy group — benefit confined to moderate-to-severely reduced LVEF subgroup; no mortality difference in normal/mildly reduced LVEF
Thyroidectomy for Type 1, mixed, and Type 2 AIT as emergency (hemodynamic instability)
Decision requires multidisciplinary team: endocrinologist, cardiologist, anaesthesiologist, high-volume thyroid surgeon
Plasma exchange as temporising measure to normalise thyroid hormones before surgery

Radioactive Iodine Therapy

Not practical short-term due to low RAI uptake in AIT
After amiodarone discontinuation, RAI timing based on urinary iodine normalisation
Recombinant TSH to boost RAI uptake in Type 1 AIT: not recommended (may worsen thyrotoxicosis by stimulating hormone release)

Back to Our Case / Patient Discussion

Type 2 AIT diagnosed based on epidemiologic data (2-year amiodarone exposure, no prior thyroid disease, negative TSH receptor antibodies, normal/unremarkable US)
Prednisone 40 mg/day started; minimal improvement at 7 days → methimazole 10 mg/day added (suspecting mixed type)
At 10 days combined therapy: TSH 0.560, FT4 1.52, T3 68 — improving
At 3 weeks: TSH 0.953, FT4 1.22, T3 63 — normal range
Amiodarone continued as essential for cardiac stability
Lesson: In critical AIT with hemodynamic instability, do not wait to determine exact type — initiate combined methimazole + prednisone empirically

Follow-up and Monitoring

Thyroid function: baseline before amiodarone initiation, then every 3 months during treatment
Continue monitoring for ≥1 year after amiodarone withdrawal (half-life ~100 days; drug accumulates in fat/muscle)
7% develop Type 2 AIT 7–16 months post-withdrawal
Type 2 on prednisolone: weekly FT3/TT3 changes; normalisation average 8 days
Type 1 on methimazole: normalisation average 4 weeks
Anticoagulation adjustments:
- Thyrotoxicosis enhances warfarin effect (↑ catabolism of vitamin K-dependent clotting factors) → bleeding risk
- Amiodarone itself inhibits CYP2C9/3A4 → impairs warfarin, rivaroxaban, and apixaban clearance
- Monitor INR and adjust anticoagulant doses; significant interaction risk with all three anticoagulant classes

Limitations of the Document

Case-based narrative review — not a systematic review or RCT; no pooled meta-analysis of outcomes
Management recommendations largely derived from observational studies and small cohorts; thyroidectomy data from single retrospective n=207 cohort
MIBI data from n=20 consecutive patients — not validated in larger populations
Combined IV/oral glucocorticoid protocol based on n=4 patients only
IV vs oral glucocorticoid comparison: n=3 patients — essentially anecdotal

Key Concepts Mentioned

concepts/Amiodarone-Induced-Thyroid-Disorders — primary topic; full Type 1/Type 2/AIH/mixed management framework
concepts/Drug-Induced-Arrhythmia — amiodarone as cause of thyroid disorder complicating existing arrhythmias

Key Entities Mentioned

entities/Amiodarone — the causative drug; updated thyroid toxicity section

Wiki Pages Updated

wiki/sources/amiodarone-thyroid-jcem-2021.md — created (this file)
wiki/concepts/Amiodarone-Induced-Thyroid-Disorders.md — created
wiki/entities/Amiodarone.md — thyroid toxicity section expanded; source added
wiki/wikiindex.md — new concept entry added
wiki/sourceindex.md — new source entry added